2044838-29-9Relevant academic research and scientific papers
BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF
-
, (2021/08/27)
The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.
Small molecule compound based on EZH2 protein degradation, and application thereof
-
, (2021/08/07)
The invention discloses a series of small molecule compounds capable of selectively degrading EZH2 protein, and application thereof. The compounds can be prepared into proper pharmaceutical dosage forms for EZH2-mediated related tumor treatment.
COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 PROTEINS
-
Page/Page column 53; 54, (2021/02/05)
The present invention relates to compounds comprising an interleukin-1 receptor-associated kinase 1 (IRAK1) protein binding moiety and a Von Hippel-Lindau (VHL) E3 ubiquitin ligase binding moiety, and associated methods of use. The compounds are useful as modulators of targeted ubiquitination, especially with respect to IRAK1, which is degraded by the compounds according to the invention.
SMARCA2-VHL DEGRADERS
-
Page/Page column 34, (2021/07/17)
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
STAT DEGRADERS AND USES THEREOF
-
Paragraph 00974; 00976, (2021/09/26)
The present invention provides compounds, compositions thereof, and methods of using the same.
Atorvastatin Derived HMG-CoA Reductase Degradation Inducing Compound
-
, (2020/12/01)
The present invention relates to a HMG-CoA reductase degradation-inducing compound and, more specifically, to a bifunctional compound in which atorvastatin and E3 ubiquitin ligase binding moiety are chemically linked as HMG-CoA reductase binding moiety, to a production method thereof, to a HMG-CoA reductase degradation method using the same, and to a pharmaceutical composition for preventing or treating HMG-CoA reductase-related diseases, comprising the same.
MERTK DEGRADERS AND USES THEREOF
-
, (2020/01/31)
The present invention provides compounds, compositions thereof, and methods of using the same.
PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS
-
Page/Page column 84; 101, (2019/11/12)
The present invention provides pyridazine derivatives of formula (I), which are therapeutically useful as SMARCA2/4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon SMARCA2/4 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the pyridazine derivatives of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof.
IRAK DEGRADERS AND USES THEREOF
-
Paragraph 1969; 1972, (2019/07/10)
The present invention provides compounds, compositions thereof, and methods of using the same.
